Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31635871 | 0.78 | KDM4E (0.40) | ALDH1A1SMN1; SMN2HPGDHSD17B10EPHX1 | |
| Hydrochloric Acid SCHEMBL31635868 | 0.78 | KDM4E (0.40) | ALDH1A1SMN1; SMN2HPGDHSD17B10EPHX1 | |
| Hydrochloric Acid SCHEMBL31635867 | 0.78 | KDM4E (0.40) | ALDH1A1SMN1; SMN2HPGDHSD17B10EPHX1 | |
| SCHEMBL25499825 | 0.75 | TLR7 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19389996 | 0.70 | LMNA (0.40) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL860798 | 0.69 | TPSAB1 (0.54) | ALDH1A1MEN1KMT2ATPSAB1 | |
| SCHEMBL1291594 | 0.69 | HPGD (0.50) | ALDH1A1MEN1KMT2AHPGDTAAR1 | |
| SCHEMBL1291430 | 0.68 | TAAR1 (0.66) | ALDH1A1MEN1KMT2AHPGDTAAR1 | |
| SCHEMBL16205822 | 0.68 | TPSAB1 (0.57) | ALDH1A1MEN1KMT2ATPSAB1 | |
| SCHEMBL16273562 | 0.67 | HTT (0.59) | ALDH1A1MEN1KMT2ATPSAB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | ALDH1A1 4478/4885MEN1 2467/4885KMT2A 2571/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | ALDH1A1 4478/4885MEN1 2467/4885KMT2A 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.